HEPA

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Hepion Pharmaceuticals Inc

NASDAQ | HEPA

0.07

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$766.94K

Market Cap

-

P/E Ratio

-46.06

EPS

$41.80

52 Week High

$0.10

52 Week Low

HEALTHCARE

Sector

HEPA Chart

Recent Chart
Price Action

HEPA Technicals

Tags:

HEPA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$31K
Total Revenue $0
Cost Of Revenue $31K
Costof Goods And Services Sold $31K
Operating Income -$19M
Selling General And Administrative $7.5M
Research And Development $12M
Operating Expenses $19M
Investment Income Net -
Net Interest Income -$1.2M
Interest Income -
Interest Expense $1.2M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$1.9M
Income Before Tax -$16M
Income Tax Expense -$3M
Interest And Debt Expense -
Net Income From Continuing Operations -$13M
Comprehensive Income Net Of Tax -
Ebit -$17M
Ebitda -$19M
Net Income -$13M

Revenue & Profitability

Earnings Performance

HEPA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.6M
Total Current Assets $1.6M
Cash And Cash Equivalents At Carrying Value $406K
Cash And Short Term Investments $406K
Inventory -
Current Net Receivables -
Total Non Current Assets $607K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.2M
Other Non Current Assets -
Total Liabilities $3.5M
Total Current Liabilities $3.1M
Current Accounts Payable $220K
Deferred Revenue -
Current Debt -
Short Term Debt $2.9M
Total Non Current Liabilities $333K
Capital Lease Obligations $0
Long Term Debt -
Current Long Term Debt $2.9M
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.9M
Other Current Liabilities $24K
Other Non Current Liabilities -
Total Shareholder Equity -$1.9M
Treasury Stock -
Retained Earnings -$238M
Common Stock $14
Common Stock Shares Outstanding $123K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$18M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $31K
Capital Expenditures $3
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$600K
Cashflow From Financing $4.3M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$13M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$31K
Total Revenue $0
Cost Of Revenue $31K
Costof Goods And Services Sold $31K
Operating Income -$19M
Selling General And Administrative $7.5M
Research And Development $12M
Operating Expenses $19M
Investment Income Net -
Net Interest Income -$1.2M
Interest Income -
Interest Expense $1.2M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$1.9M
Income Before Tax -$16M
Income Tax Expense -$3M
Interest And Debt Expense -
Net Income From Continuing Operations -$13M
Comprehensive Income Net Of Tax -
Ebit -$17M
Ebitda -$19M
Net Income -$13M

HEPA Profile

Hepion Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company based in Edison, New Jersey, focused on developing innovative therapies for chronic liver diseases, particularly non-alcoholic steatohepatitis (NASH). The company boasts a robust pipeline driven by its advanced drug discovery and development platforms, aimed at addressing significant unmet medical needs in hepatology. Its lead candidate, CRV431, demonstrates considerable promise in the treatment of liver conditions, positioning Hepion as a notable contender in the expanding market for liver therapeutics and underscoring its commitment to improving patient outcomes.

VHAI
0.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
CGBS
-39.47%
$0.03
PLUG
-9.61%
$3.48
YDKG
-49.73%
$0.09
NVDA
+1.10%
$181.81
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.52%
$3.09
NIO
+0.14%
$6.83
BBD
+1.87%
$3.26
MIRA
+36.36%
$1.80
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
AADI
+24.28%
$2.61
FEMY
+35.37%
$0.74
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.14%
$22.50
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
SOFI
-5.10%
$26.60
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
DFLI
-32.48%
$1.33
AMD
-1.69%
$234.56
AXDX
-61.36%
$0.03
ETHD
+5.82%
$4.00
GDXD
-10.23%
$0.60
RIG
-2.41%
$3.23
AAL
-4.88%
$11.89
MARA
-11.27%
$20.26
CLF
-2.79%
$13.56
BTG
+4.76%
$5.94
LAES
-15.08%
$6.36
BTBT
-9.11%
$3.69
AMC
-2.48%
$2.75
GNPX
-43.39%
$0.47
RF
-5.61%
$23.35
QBTS
-9.64%
$40.46
ABAT
-36.64%
$5.67
QS
-13.38%
$15.46
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
NAK
-15.15%
$2.24
LGCB
+19.39%
$1.97
GPUS
-5.78%
$0.36
RGTZ
+29.08%
$11.23
HBAN
-5.18%
$15.37
CIFR
-10.98%
$18.72
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
BAC
-3.51%
$50.44
WOK
+1.55%
$0.05
UUUU
-13.20%
$21.69
CRML
-14.52%
$19.42
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
PLTR
-0.83%
$178.12
T
+0.49%
$26.20
SOUN
-2.99%
$20.76
MU
+5.51%
$202.53
AMZN
-0.51%
$214.47
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.83%
$47.64
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
GRAB
-3.54%
$5.71
RMBL
+60.50%
$3.21
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.53%
$5.68
HIMS
-5.75%
$59.15
ADD
-25.47%
$0.05
AUUD
+0.97%
$2.06
SOND
+79.34%
$1.65
SLNH
-2.33%
$4.19
JOBY
-8.69%
$16.07
CRWV
+1.79%
$141.74
TOVX
-48.67%
$0.43
IONQ
-9.41%
$65.59
SATL
-29.71%
$2.91
SRM
+53.27%
$10.30
VHAI
0.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.09%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
CGBS
-39.47%
$0.03
PLUG
-9.61%
$3.48
YDKG
-49.73%
$0.09
NVDA
+1.10%
$181.81
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.52%
$3.09
NIO
+0.14%
$6.83
BBD
+1.87%
$3.26
MIRA
+36.36%
$1.80
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
AADI
+24.28%
$2.61
FEMY
+35.37%
$0.74
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.14%
$22.50
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
SOFI
-5.10%
$26.60
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
DFLI
-32.48%
$1.33
AMD
-1.69%
$234.56
AXDX
-61.36%
$0.03
ETHD
+5.82%
$4.00
GDXD
-10.23%
$0.60
RIG
-2.41%
$3.23
AAL
-4.88%
$11.89
MARA
-11.27%
$20.26
CLF
-2.79%
$13.56
BTG
+4.76%
$5.94
LAES
-15.08%
$6.36
BTBT
-9.11%
$3.69
AMC
-2.48%
$2.75
GNPX
-43.39%
$0.47
RF
-5.61%
$23.35
QBTS
-9.64%
$40.46
ABAT
-36.64%
$5.67
QS
-13.38%
$15.46
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
NAK
-15.15%
$2.24
LGCB
+19.39%
$1.97
GPUS
-5.78%
$0.36
RGTZ
+29.08%
$11.23
HBAN
-5.18%
$15.37
CIFR
-10.98%
$18.72
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
BAC
-3.51%
$50.44
WOK
+1.55%
$0.05
UUUU
-13.20%
$21.69
CRML
-14.52%
$19.42
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
PLTR
-0.83%
$178.12
T
+0.49%
$26.20
SOUN
-2.99%
$20.76
MU
+5.51%
$202.53
AMZN
-0.51%
$214.47
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.83%
$47.64
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
GRAB
-3.54%
$5.71
RMBL
+60.50%
$3.21
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.53%
$5.68
HIMS
-5.75%
$59.15
ADD
-25.47%
$0.05
AUUD
+0.97%
$2.06
SOND
+79.34%
$1.65
SLNH
-2.33%
$4.19
JOBY
-8.69%
$16.07
CRWV
+1.79%
$141.74
TOVX
-48.67%
$0.43
IONQ
-9.41%
$65.59
SATL
-29.71%
$2.91
SRM
+53.27%
$10.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.